[go: up one dir, main page]

UA84749C2 - Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents

Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Info

Publication number
UA84749C2
UA84749C2 UAA200611678A UAA200611678A UA84749C2 UA 84749 C2 UA84749 C2 UA 84749C2 UA A200611678 A UAA200611678 A UA A200611678A UA A200611678 A UAA200611678 A UA A200611678A UA 84749 C2 UA84749 C2 UA 84749C2
Authority
UA
Ukraine
Prior art keywords
heading
treatment
normal
receptor antagonists
inflammatory diseases
Prior art date
Application number
UAA200611678A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Эми М. Элдер
Кевин Т. Спротт
Син Дж. Харрисон
Фредерик А. Хикс
Кристелль С. Рену
Доминик Рейнольдс
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of UA84749C2 publication Critical patent/UA84749C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed herein are compounds represented by Structural Formula: (I) and (I-А). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply "CRTH2" for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-А) are defined herein.
UAA200611678A 2004-04-07 2005-04-07 Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES UA84749C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56041004P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
UA84749C2 true UA84749C2 (en) 2008-11-25

Family

ID=34965223

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611678A UA84749C2 (en) 2004-04-07 2005-04-07 Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Country Status (21)

Country Link
EP (1) EP1740547A1 (en)
JP (1) JP2007532555A (en)
KR (1) KR20070002085A (en)
CN (1) CN101018770A (en)
AR (1) AR048528A1 (en)
AU (1) AU2005233125A1 (en)
BR (1) BRPI0509668A (en)
CA (1) CA2561564A1 (en)
CL (1) CL2008000069A1 (en)
CR (1) CR8659A (en)
EC (1) ECSP066977A (en)
IL (1) IL178328A0 (en)
MA (1) MA28566B1 (en)
MX (1) MXPA06011540A (en)
NO (1) NO20065107L (en)
RU (1) RU2006138603A (en)
TN (1) TNSN06320A1 (en)
TW (1) TW200538127A (en)
UA (1) UA84749C2 (en)
WO (1) WO2005100321A1 (en)
ZA (1) ZA200608955B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
AU2006274884B2 (en) 2005-07-29 2012-04-05 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
ES2618352T3 (en) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of androgenetic alopecia
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
WO2008029924A1 (en) 2006-09-08 2008-03-13 Dainippon Sumitomo Pharma Co., Ltd. Cyclic aminoalkylcarboxamide derivative
CA2662574A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
EP2121671A1 (en) 2006-12-20 2009-11-25 Novartis AG 2-substituted 5-membered heterocycles as scd inhibitors
US20100222347A1 (en) 2007-09-27 2010-09-02 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient
ATE502920T1 (en) 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd INDOLES AND THEIR THERAPEUTIC USE
JP2011102241A (en) * 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd Novel 1-aminocarbonylpiperidine derivative
WO2010022320A2 (en) 2008-08-22 2010-02-25 Baxter International Inc. Polymeric benzyl carbonate-derivatives
JP2011256110A (en) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd Manufacturing method of hexahydropyrroloquinoline
EP2415764A4 (en) 2009-03-31 2012-08-08 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING A TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9360482B2 (en) 2009-11-05 2016-06-07 Glaxosmithkline Llc Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4
ES2553871T3 (en) 2010-07-05 2015-12-14 Actelion Pharmaceuticals Ltd. 1-Phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
PE20140788A1 (en) 2011-06-17 2014-07-09 Merck Sharp & Dohme CYCLOALKYL CONDENSED TETRAHYDROQUINOLINES AS CRTH2 RECEPTOR MODULATORS
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013093842A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JP6127135B2 (en) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 1-Phenyl substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
BR112018002012A2 (en) 2015-07-30 2018-09-18 Univ Pennsylvania human dp-2 gene single nucleotide polymorphic alleles for detection of susceptibility to pgd2 hair growth inhibition
JOP20190105A1 (en) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
CN111989325B (en) 2018-04-18 2025-02-25 星座制药公司 Regulators of methyl modification enzymes, compositions and uses thereof
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP4003532B1 (en) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
CN113201316B (en) * 2021-04-25 2022-08-26 西南石油大学 temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof
CN116425623B (en) * 2023-04-10 2024-02-13 大连凯飞化学股份有限公司 Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2186065C1 (en) * 1998-03-31 2002-07-27 Сионоги Энд Ко., Лтд. Method of synthesis of derivatives of 5-hydroxy-benzo[b]thiophene-3- carboxylic acid (variants) and thiophenic acid derivatives
YU84303A (en) * 2001-04-30 2006-05-25 Pfizer Products Inc. Methods for preparing cetp inhibitors
JP2003321471A (en) * 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd Lactam compound and method of production for the same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
CA2500582A1 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
AU2003289207A1 (en) * 2002-12-06 2004-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
TW200538127A (en) 2005-12-01
NO20065107L (en) 2006-12-01
CN101018770A (en) 2007-08-15
JP2007532555A (en) 2007-11-15
AU2005233125A1 (en) 2005-10-27
MA28566B1 (en) 2007-05-02
MXPA06011540A (en) 2007-01-26
RU2006138603A (en) 2008-05-20
IL178328A0 (en) 2007-02-11
CL2008000069A1 (en) 2008-05-16
ZA200608955B (en) 2009-05-27
CR8659A (en) 2007-06-08
CA2561564A1 (en) 2005-10-27
BRPI0509668A (en) 2007-10-09
TNSN06320A1 (en) 2008-02-22
KR20070002085A (en) 2007-01-04
AR048528A1 (en) 2006-05-03
EP1740547A1 (en) 2007-01-10
ECSP066977A (en) 2006-12-29
WO2005100321A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
UA84749C2 (en) Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2004032848A3 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
MX2007003335A (en) Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof.
NO20074961L (en) Imidazopyridazinforbindelser
BRPI0408369A (en) indole derivatives useful for treating disease
NO20072831L (en) Imidazo [1,2-A] Pyridine Compounds, Compositions, Uses and Methods Related thereto
ATE250577T1 (en) INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS
WO2004098589A8 (en) 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
EA200700047A1 (en) NEW ALKYL DERIVATIVES AS METABOTROPIC GLUTAMAT RECEPTORS
CA2503900A1 (en) Purine compounds and use thereof as cannabinoid receptor ligands
EA200401309A1 (en) TRYZE-SUBSTITUTED HETEROARILES AND METHODS OF THEIR RECEPTION AND APPLICATION
MX2007007220A (en) Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders.
NO20055649L (en) Substituted dihydroquinazoline with antivial properties
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
EA200500173A1 (en) 3,6-DISPOSABLE AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS ANTAGONISTS OF MUSCARIN RECEPTORS
MY141200A (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE323686T1 (en) SUBSTITUTED 2-ARYLBENZAZOLES AND THEIR USE AS ANTITUMORAL AGENTS
TW200640869A (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
BRPI0409393A8 (en) compound, pharmaceutical composition, and methods for modulating chemokine receptor activity in a mammal for treating, ameliorating, controlling or reducing the risk of an inflammatory and immunoregulatory disorder or disease, and rheumatoid arthritis
WO2004058174A3 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EA200600071A1 (en) Derivatives of N-phenylpyrazine and Methods for the Prevention or Treatment of Diseases Associated with 5HT-Receptor
FR2817256B1 (en) DERIVATIVES OF 4-HYDROXYBUTANOIC ACID AND ITS SUPERIOR APPROACHES AS GAMMA-HYDROXYBUTYRATE (GHB) RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND PHARMACEUTICAL USES
BR0309551A (en) Substituted Pyrazine Derivatives
BRPI0409505A (en) compounds as crf1 receptor antagonists